227 related articles for article (PubMed ID: 15953371)
1. Transforming growth factor-beta and malignant melanoma: molecular mechanisms.
Hussein MR
J Cutan Pathol; 2005 Jul; 32(6):389-95. PubMed ID: 15953371
[TBL] [Abstract][Full Text] [Related]
2. Crossing Smads.
Wrana JL
Sci STKE; 2000 Mar; 2000(23):re1. PubMed ID: 11752591
[TBL] [Abstract][Full Text] [Related]
3. Independent regulation of growth and SMAD-mediated transcription by transforming growth factor beta in human melanoma cells.
Rodeck U; Nishiyama T; Mauviel A
Cancer Res; 1999 Feb; 59(3):547-50. PubMed ID: 9973198
[TBL] [Abstract][Full Text] [Related]
4. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis.
Javelaud D; Mauviel A
Oncogene; 2005 Aug; 24(37):5742-50. PubMed ID: 16123807
[TBL] [Abstract][Full Text] [Related]
5. Cytoplasmic localization of the oncogenic protein Ski in human cutaneous melanomas in vivo: functional implications for transforming growth factor beta signaling.
Reed JA; Bales E; Xu W; Okan NA; Bandyopadhyay D; Medrano EE
Cancer Res; 2001 Nov; 61(22):8074-8. PubMed ID: 11719430
[TBL] [Abstract][Full Text] [Related]
6. c-Ski inhibits the TGF-beta signaling pathway through stabilization of inactive Smad complexes on Smad-binding elements.
Suzuki H; Yagi K; Kondo M; Kato M; Miyazono K; Miyazawa K
Oncogene; 2004 Jun; 23(29):5068-76. PubMed ID: 15107821
[TBL] [Abstract][Full Text] [Related]
7. Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes.
Deacu E; Mori Y; Sato F; Yin J; Olaru A; Sterian A; Xu Y; Wang S; Schulmann K; Berki A; Kan T; Abraham JM; Meltzer SJ
Cancer Res; 2004 Nov; 64(21):7690-6. PubMed ID: 15520171
[TBL] [Abstract][Full Text] [Related]
8. Signaling cross-talk between IGF-binding protein-3 and transforming growth factor-(beta) in mesenchymal chondroprogenitor cell growth.
O'Rear L; Longobardi L; Torello M; Law BK; Moses HL; Chiarelli F; Spagnoli A
J Mol Endocrinol; 2005 Jun; 34(3):723-37. PubMed ID: 15956343
[TBL] [Abstract][Full Text] [Related]
9. Influence of melanoma inhibitory activity on transforming growth factor-beta signaling in malignant melanoma.
Rothhammer T; Bosserhoff AK
Melanoma Res; 2006 Aug; 16(4):309-16. PubMed ID: 16845326
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-beta and Smad signalling in kidney diseases.
Wang W; Koka V; Lan HY
Nephrology (Carlton); 2005 Feb; 10(1):48-56. PubMed ID: 15705182
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.
Kalo E; Buganim Y; Shapira KE; Besserglick H; Goldfinger N; Weisz L; Stambolsky P; Henis YI; Rotter V
Mol Cell Biol; 2007 Dec; 27(23):8228-42. PubMed ID: 17875924
[TBL] [Abstract][Full Text] [Related]
12. TGF-beta signalling from cell membrane to nucleus through SMAD proteins.
Heldin CH; Miyazono K; ten Dijke P
Nature; 1997 Dec; 390(6659):465-71. PubMed ID: 9393997
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor beta signal transduction.
Dennler S; Goumans MJ; ten Dijke P
J Leukoc Biol; 2002 May; 71(5):731-40. PubMed ID: 11994497
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor-beta signaling in cancer.
Rich J; Borton A; Wang X
Microsc Res Tech; 2001 Feb; 52(4):363-73. PubMed ID: 11170295
[TBL] [Abstract][Full Text] [Related]
15. TGF-beta-induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing.
Schiller M; Javelaud D; Mauviel A
J Dermatol Sci; 2004 Aug; 35(2):83-92. PubMed ID: 15265520
[TBL] [Abstract][Full Text] [Related]
16. Mammalian transforming growth factor-betas: Smad signaling and physio-pathological roles.
Javelaud D; Mauviel A
Int J Biochem Cell Biol; 2004 Jul; 36(7):1161-5. PubMed ID: 15109563
[TBL] [Abstract][Full Text] [Related]
17. Non-Smad TGF-beta signals.
Moustakas A; Heldin CH
J Cell Sci; 2005 Aug; 118(Pt 16):3573-84. PubMed ID: 16105881
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of TGF-beta responsive genes by Smad-interacting peptide aptamers from FoxH1, Lef1 and CBP.
Cui Q; Lim SK; Zhao B; Hoffmann FM
Oncogene; 2005 Jun; 24(24):3864-74. PubMed ID: 15750622
[TBL] [Abstract][Full Text] [Related]
19. RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD.
Chi XZ; Yang JO; Lee KY; Ito K; Sakakura C; Li QL; Kim HR; Cha EJ; Lee YH; Kaneda A; Ushijima T; Kim WJ; Ito Y; Bae SC
Mol Cell Biol; 2005 Sep; 25(18):8097-107. PubMed ID: 16135801
[TBL] [Abstract][Full Text] [Related]
20. An imbalance between Smad and MAPK pathways is responsible for TGF-beta tumor promoting effects in high-grade gliomas.
Nickl-Jockschat T; Arslan F; Doerfelt A; Bogdahn U; Bosserhoff A; Hau P
Int J Oncol; 2007 Feb; 30(2):499-507. PubMed ID: 17203233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
